PepGen Q1 loss narrows as operating expenses fall

PepGen

12/05/2026 21:14

Overview

US biotechnology firm's Q1 net loss narrowed yr/yr as operating expenses declined

Company ended Q1 with $132.3 mln in cash, seen funding operations into 2H 2027

Outlook

PepGen expects data from the FREEDOM2 10 mg/kg cohort in 2H 2026

Company anticipates 12.5 mg/kg cohort data from FREEDOM2 in 2027

PepGen says cash is sufficient to fund operations into 2H 2027

Result Drivers

LOWER R&D SPENDING - Research and development expenses fell to $13.0 mln from $25.4 mln a yr earlier

REGULATORY DEVELOPMENTS - FDA placed a partial clinical hold on FREEDOM2 study; co said trial timing not impacted and it is working to address agency's questions

Company press release: ID:nBwb0Jtyva

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.26
Q1 Net Income
-$17.76 mln
Q1 Operating Expenses
$18.94 mln
Q1 Operating Income
-$18.94 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for PepGen Inc is $10.00, about 488.2% above its May 11 closing price of $1.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)